Jefferies Reiterates Buy on Dicerna Pharma (DRNA) Following 4Q - PT to $19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Dicerna Pharma (DRNA) Tops Q4 EPS by 8c
March 10, 2016 4:10 PM ESTDicerna Pharma (NASDAQ: DRNA) reported Q4 EPS of ($0.76), $0.08 better than the analyst estimate of ($0.84).
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
... MoreTrading Radar for 3/10: Dollar General (DG), Canadian Solar (CSIQ), Plug Power (PLUG), Veifone (PAY) Report
March 9, 2016 2:56 PM ESTThe Trading Radar highlights key earnings and economic announcements for the next trading session:
Before Markets Open:
Economics:
8:30am EST
Earnings:
BioLineRx (Nasdaq: BLRX) - consensus loss $0.06
CECO Environmental (Nasdaq: CECE) - consensus EPS $0.21
Canadian Solar (Nasdaq: CSIQ) - consensus EPS $0.76
Cantel Medical (NYSE: CMN) - consensus EPS $0.34
Cardiome Pharma (Nasdaq:... More
